Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
uniQure ( (QURE) ) has shared an update.
uniQure N.V. has commenced the dosing of the first patient in its Phase I/IIa clinical trial of AMT-260, a promising gene therapy for refractory mesial temporal lobe epilepsy, a condition affecting many with limited treatment options. AMT-260 aims to reduce seizures via a one-time administration, offering hope for those unresponsive to existing treatments. As the trial continues, uniQure anticipates further program updates soon.
See more insights into QURE stock on TipRanks’ Stock Analysis page.